Sepalna
Authorised
senaparib
MedicineHumanAuthorised
Icelandic is available via eTranslation, the European Commission's machine translation service.
Translate to Icelandic | Important information about machine translation
Sepalna is a cancer medicine used on its own in adults with the following cancers:
It is used in adults whose cancer is advanced, high-grade (fast-growing) and in whom the cancer has shrunk or there is no detectable sign of it after a platinum-based treatment.
Sepalna contains the active substance senaparib.
Sepalna can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the use of cancer medicines.
It is available as capsules to be taken by mouth once daily. Patients should start treatment with Sepalna no later than 8 weeks after completing the final dose of their platinum-based chemotherapy.
Patients can continue Sepalna treatment until scans show disease worsening, they develop unacceptable side effects or they have completed 2 years of treatment.
For more information about using Sepalna, see the package leaflet or contact your doctor or pharmacist.
The active substance in Sepalna, senaparib, blocks the action of a protein called human poly ADP ribose polymerase (PARP), which helps to repair damaged DNA in both healthy cells and cancer cells when they divide and grow. Blocking PARP prevents cancer cells from repairing their DNA. This causes the cancer cells to die, which helps to control the cancer.
In a main study, Sepalna was shown to prolong the time people lived without their cancer worsening compared with placebo (a dummy treatment).
The study involved 404 adults with advanced high-grade epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer which had cleared (partially or completely) after treatment with platinum-based chemotherapy. They received Sepalna within 8 weeks after the last dose of chemotherapy. Although the results were not yet final at the time of analysis, there was an estimated difference of at least 11 months in favour of Sepalna in how long patients lived without their disease worsening between the two groups, with a median time living without the disease coming back of 13.6 months in people who received placebo.
Studies carried out with Sepalna are described in more detail in the medicine’s assessment report.
For the full list of side effects and restrictions with Sepalna, see the package leaflet.
The most common side effects with Sepalna (which may affect more than 1 in 10 people) include anaemia (low levels of red blood cells), leucopenia (low levels of white blood cells), neutropenia (low levels of neutrophils, a type of white blood cell), thrombocytopenia (low levels of blood platelets, components that help the blood to clot), nausea (feeling sick), increased blood levels of liver enzymes (which may indicate liver problems), tiredness, abdominal (belly) pain, vomiting, dizziness, diarrhoea, reduced appetite, lymphopenia (low levels of lymphocytes, a type of white blood cell), upper respiratory tract (nose and throat) infection, haematuria (blood in the urine), hyperbilirubinaemia (high blood levels of bilirubin, a breakdown product of red blood cells), which may indicate liver problems, headache and arthralgia (joint pain).
Sepalna must not be used when breast-feeding.
When used as maintenance treatment in patients with advanced high-grade epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who responded to their first course of chemotherapy, Sepalna was shown to increase the time people live without their disease worsening, compared with placebo. At the time of authorisation, data from the main study on how long people lived overall following treatment with Sepalna were not yet available. However, the company has been requested to submit these results from the main study once they are available. In terms of safety, the side effects of Sepalna are primarily blood-related and can be managed with dose reduction or treatment interruption.
The European Medicines Agency therefore decided that Sepalna’s benefits are greater than its risks and that it can be authorised for use in the EU.
The company that markets Sepalna will provide the final results from the main study on how long patients lived overall to better understand the benefits of Sepalna.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sepalna have also been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Sepalna are continuously monitored. Suspected side effects reported with Sepalna are carefully evaluated and any necessary action is taken to protect patients.
Sepalna received a marketing authorisation valid throughout the EU on 12 November 2026.
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
Sepalna is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.